YMRC
TGTX icon

Yorktown Management & Research Company’s TG Therapeutics TGTX Stock Holding History

Yorktown Management & Research Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$753K Hold
13,700
– – 0.46% 66
2026
Q1 		$455K Buy
13,700
+3,050
+29% +$90.9K 0.38% 91
2025
Q4 		$317K Hold
10,650
– – 0.25% 165
2025
Q3 		$385K Hold
10,650
– – 0.31% 128
2025
Q2 		$383K Buy
+10,650
New +$396K 0.37% 120

Other funds holding TGTX

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Yorktown Management & Research Company's TGTX Position: Q2 2026 in Review

Yorktown Management & Research Company held its TG Therapeutics (TGTX) position steady in Q2 2026 at 13,700 shares worth $753K. The position accounts for 0.46% of the portfolio, ranked #66.

Yorktown Management & Research Company first reported a position in TGTX in Q2 2025 and has held it in 5 quarters since. 144 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Yorktown Management & Research Company held 13,700 shares of TG Therapeutics worth $753K as of Q2 2026.
  • Yorktown Management & Research Company left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up 0.46% of Yorktown Management & Research Company's portfolio in Q2 2026, its #66 holding.
  • Yorktown Management & Research Company first reported a position in TG Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 144 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.